Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008

Maturitas

Volumn 74, Issue 1, 2013, Pages 74-78

  Salgueiro, M Esther ^a   Manso, Gloria ^a   Castells, Xavier ^c   Jimeno, Francisco J ^a   Ordoñez, Lucía ^a   González, Verónica ^b   Rodríguez, Alfonso ^b   Capellà, Dolors ^c  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b Division de Farmacoepidemiologia y Farmacovigilancia   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

Author keywords

Defined daily doses; Osteoporosis; Pharmacological treatment

Indexed keywords

ALENDRONIC ACID; CALCITONIN; COLECALCIFEROL; ELCATONIN; ESTRADIOL; ESTRIOL; ESTRIOL CONJUGATED ESTROGEN; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG USE; DRUG UTILIZATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OSTEOPOROSIS; SPAIN; TREND STUDY;

BONE DENSITY CONSERVATION AGENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPAIN;

EID: 84870897980     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.10.002     Document Type: Article

References (31)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy Journal of the American Medical Association 285 6 2001 785 795
2. A.D. Woolf, and B. Pfleger Burden of major musculoskeletal conditions Bulletin of the World Health Organization 81 9 2003 646 656
3. J.A. Kanis, O. Johnell, C. De Laet, B. Jonsson, A. Oden, and A.K. Ogelsby International variations in hip fracture probabilities: implications for risk assessment Journal of Bone and Mineral Research 17 7 2002 1237 1244
4. FRAX: WHO Fracture Risk Assesment Tool. University of Sheffield. Available on: http://www.shef.ac.uk/FRAX/index.jsp [accessed 15.02.12]
5. D.K. Roy, T.W. O'Neill, and J.D. Finn Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS) Osteoporosis International 14 1 2003 19 26
6. Spanish Agency of Medicines and Health Products. Strontium Ranelate (Protelos, Osseor): risk of severe hypersensitivity adverse reactions. Information Sheet Ref: 2007/17. Available on: http://www.aemps.gob.es/informa/ notasInformativas/medicamentosUsoHumano/seguridad/2007/docs/NI-2007-17-protelos- osseor.pdf [accessed 15.02.12]
7. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial Journal of the American Medical Association 288 3 2002 321 323
8. V. Beral Million Women Study Collaborators, Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 9382 2003 419 427
9. Spanish Agency of Medicines and Health Products. Risks and benefits of hormone therapy replacement with oestrogens associated with progestagens: new data. Information Sheet Ref: 2002/07. Available on: http://www.aemps.gob.es/ informa/notasInformativas/medicamentosUsoHumano/seguridad/2002/docs/ THS-estrogenos-progestagenos-PS.pdf [accessed 15.02.12]
10. Spanish Agency of Medicines and Health Products. Restriction of the therapeutic indications to hormone replacement treatment. Information Sheet Ref: 2004/01. Available on: http://www.aemps.gob.es/informa/notasInformativas/ medicamentosUsoHumano/seguridad/2004/docs/NI-2004-01-THS-restriccion.pdf [accessed 15.02.12]
11. Spanish Agency of Medicines and Health Products. Hormonal therapy on menopause: update information. Information Sheet Ref: 2008/16. Available on: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2008/NI-2008-16-terapia-hormonal.htm [accessed 15.02.12]
12. A. Qaseem, V. Snow, and P. Shekelle Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians Annals of Internal Medicine 149 6 2008 404 415
13. Working Group of the Clinical Practice Guideline on Prevention of Osteoporosis and fragility fractures. Clinical Practice Guideline on Prevention of Osteoporosis and fragility fractures. Quality Plan for the National Health System of the Ministry of Health, Social Policy and Equality. Agència d'Informació, Avaluació i Qualitat en Salut (AIAQS) de Cataluña; 2010. Guide of Clinical Practice of the National Health Service: AATRM N 2007/02. Available on: http://www.gencat.cat/salut/depsan/units/aatrm/ pdf/gpc-osteoporosi-aatrm2010-vcompleta.pdf [accessed 15.02.12]
14. Centre of online Information of Medicines, CIMA. Spanish Agency of Medicines and Health Products. Available on: http://www.aemps.gob.es/ [accessed 15.02.12]
15. WHO Collaborating Centre for Drug Statistics Methodology. Available on: http://www.whocc.no/atc-ddd-index/ [accessed 15.02.12]
16. J. Pérez, N. Marín, A. Vallano, X. Castells, and D. Capellà Consumption and cost of antipsychotic drugs Actas Espanolas de Psiquiatria 33 2 2005 110 116
17. R.S. Stafford, R.L. Drieling, and A.L. Hersh National trends in osteoporosis visits and osteoporosis treatment, 1988-2003 Archives of Internal Medicine 164 14 2004 1525 1530
18. M.P. Guay, A. Dragomir, D. Pilon, Y. Moride, and S. Perreault Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication Pharmacoepidemiology and Drug Safety 16 1 2007 17 27
19. E. Lokkegaard, O. Lidegaard, L.N. Moller, C. Agger, A.H. Andreasen, and T. Jorgensen Hormone replacement therapy in Denmark, 1995-2004 Acta Obstetricia et Gynecologica Scandinavica 86 11 2007 1342 1351
20. J.F. Farley, S.J. Blalock, and R.R. Cline Effect of the women's health initiative on prescription anti-osteoporosis medication utilization Osteoporosis International 19 11 2008 1603 1612
21. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women New England Journal of Medicine 355 2 2006 125 137
22. J.A. Kanis, E.V. McCloskey, B. Jonsson, A. Cooper, O. Ström, and F. Borgström An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women Arch Osteoporos 5 2010 19 48
23. O. Rocha, N. Lunet, L. Costa, and H. Barros Osteoporosis treatment in Portugal: trends and geographical variation Acta Medica Portuguesa 19 5 2006 373 380
24. A.P. Jonville-Béra, B. Crickx, L. Aaron, I. Hartingh, and E. Autret-Leca Strontium ranelate-induced DRESS syndrome: first two case reports Allergy 64 4 2009 658 659
25. E. Carracedo-Martínez, and A. Pía-Morandeira Impact of a health safety warning on strontium ranelate utilization Gaceta Sanitaria 24 2 2010 151 153
26. L.H. Martín Arias, C. Treceño, and P. García-Ortega Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study European Journal of Clinical Pharmacology 2012 10.1007/s00228-012-1337-z
27. S.A. Hollingworth, I. Gunanti, L.M. Nissen, and E.L. Duncan Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data Drugs and Aging 27 3 2010 255 264
28. Spanish Agency of Medicines and Health Products. Recommendations for the prevention of jaw osteonecrosis associated with bisphosphonate therapy. Information Sheet Ref: 2009/10. Available on: http://www.aemps.gob.es/informa/ notasInformativas/medicamentosUsoHumano/seguridad/2009/docs/NI-2009-10- bisfosfonatos.pdf [accessed 06.06.12]
29. Spanish Health Ministry ATC subgroups and drugs of high consumption in the National Health System in 2009 Información Terapeútica del Sistema Nacional de Salud 34 2010 89 92 Available on: http://www.msc.es/ biblioPublic/publicaciones/recursos-propios/infMedic/docs/ vol34n3SubgrATCppiosActivos.pdf [accessed 06.06.12]
30. Spanish Health Ministry ATC subgroups and drugs of high consumption in the National Health System in 2010 Información Terapeútica del Sistema Nacional de Salud 35 2011 124 128 Available on: http://www.msc.es/ biblioPublic/publicaciones/recursos-propios/infMedic/docs/SubgruposATCvol35n4. pdf [accessed 06.06.12]
31. Spanish Agency of Medicines and Health Products. Bisphosphonates and fracture risk atypical femur. Information Sheet Ref: 2011/04. Available on: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2011/docs/NI-MUH-04-2011.pdf [accessed 06.06.12]